Skip to main content

Table 3 Consent to treatment

From: Retrospective agreement and consent to neurocritical care is influenced by functional outcome

 

Ischemia

ICH

SAH

Meningoencephalitis

Epilepsy

GBS/MG

Neurodeg./

Enceph.

Cerebral

neoplasm

Intox.

mRS 0-1 (n, %)

24/25 (96.0)

28/30 (93.3)

9/9 (100.0)

23/24 (95.87)

44/49 (89.8)

10/10 (100.0)

1/1 (100.0)

0/0

7/7 (100.0)

mRS 2-3 (n, %)

35/44 (79.9)

13/17 (76.5)

1/2 (50.0)

5/7 (71.4)

1/4 (25.0)

7/9 (77.8)

2/3 (66.7)

2/2 (100.0)

7/8 (87.5)

mRS 4-5 (n, %)

4/68 (5.8)

3/41 (7.3)

4/8 (50.0)

5/9 (55.6)

8/19 (42.1)

1/4 (25.0)

2/6 (33.3)

1/2 (50.0)

2/4 (50.0)

mRS 6

(n, %)

35/104 (33.7)

32/117 (27.4)

9/18 (50.0)

5/7 (71.4)

9/14 (64.3)

1/1 (100.0)

6/10 (60.0)

11/15 (73.3)

4/6 (66.7)

  1. Consent to treatment (%) according to diagnosis and separated by functional outcome, that is, the proportion of patients with a specific disease and with a specific outcome who retrospectively agreed and consented to neurocritical care.
  2. ICH, Intracranial hemorrhage; SAH, subarachnoid hemorrhage; GBS, Guillain-Barré syndrome; MG, myasthenia gravis; neurodeg, neurodegenerative disease; Enceph, encephalopathy; Intox, intoxication; n, number; mRS, modified Rankin Scale.
Back to article page

Critical Care

ISSN: 1364-8535